bannerHON
img
HONnews
HONnews
img PATIENT / PARTICULIER img PROFESSIONNEL DE SANTE img WEBMESTRE img
img
 
img
HONcode sites
Khresmoi - new !
HONselect
News
Conferences
Images

Themes:
A B C D E F G H I
J K L M N O P Q
R S T U V W X Y Z
Browse archive:
2017: O S A J J M A M F J
2016: D N O

 
  Other news for:
Leukemia
Neoplasms
Physicians
 Resources from HONselect
Can Drug Company Perks Sway Cancer Docs' Prescriptions?
Even relatively small payments seemed to make a difference, researchers report

By Dennis Thompson
HealthDay Reporter

TUESDAY, June 6, 2017 (HealthDay News) -- Cancer doctors who receive freebies from pharmaceutical companies are more likely to prescribe drugs produced by those companies, a new study reports.

Free meals, paid travel expenses and fees for consulting or lecturing appeared to influence which drugs a doctor would choose when treating two different types of cancer, said study lead researcher Dr. Aaron Mitchell.

Specifically, doctors were 78 percent more likely to prescribe a drug to treat kidney cancer that had spread if they'd received a gift or small payment from that drug's manufacturer, compared to physicians who didn't receive any payments, Mitchell said.

The doctors also were 29 percent more likely to prescribe a drug for chronic myeloid leukemia if they'd received meals, travel or speaking fees from the drug's maker, Mitchell said.

"This raises the possibility that drug companies are able to influence prescribing practices through gifts to physicians," he said.

Mitchell is a fellow with the University of North Carolina School of Medicine.

Dr. Richard Schilsky, chief medical officer of the American Society of Clinical Oncology (ASCO), was not surprised by the findings.

"This is why drug companies do what they do," Schilsky said, adding that he hopes the findings will "raise awareness among doctors that they are susceptible to these influences."

Previous research has indicated that drug company gifts can influence doctors to choose pricey brand-name drugs over cheaper generics, Mitchell said during his Saturday presentation of the study.

Mitchell and his colleagues decided to see if such influence occurred in cancer treatment, where the stakes can be higher.

"The drugs we use are far more toxic and far more expensive to our patients, and hence any decision between different drugs takes on greater weight," Mitchell said.

The researchers chose to focus on kidney cancer and chronic myeloid leukemia because doctors can choose between one of three different drugs to treat these cancers, Mitchell said.

The drugs work equally well, but have differences in side effects that would be noticeable to a patient, Mitchell said.

The research team reviewed data from the U.S. Center for Medicare & Medicaid Services to track individual cancer doctors' prescribing patterns in 2013 and 2014 for those diseases.

They then compared those prescribing patterns against data from Open Payments, a database created under the Affordable Care Act through which drug and medical device manufacturers must disclose any payments greater than $10 to doctors or teaching hospitals.

The researchers found almost 1,400 doctors who had received payments and prescribed cancer drugs, and about 800 doctors who had prescribed cancer medications but hadn't received any payments.

It turned out the payments did appear to influence doctors' choice of drug, even though the payouts tended to be small. Payments were about $566, on average, per doctor from kidney cancer drug makers, and $166 from makers of drugs to treat chronic myeloid leukemia, the study authors said.

"Even for physicians who received very small payments, we still saw a change in prescription rates," Mitchell said. "It looks like this shakes out to be a really good buy for a drug company."

Interestingly, the researchers found mixed results when they looked at direct research funding that doctors received from drug makers.

Research funding appeared to influence drug choice for treatment of kidney cancer, but not chronic myeloid leukemia, the researchers found. However, average research funding provided for kidney cancer per doctor (about $33,000) was far less than that for leukemia (almost $186,000).

Dr. Dawn Hershman leads the breast cancer program at Columbia University's Herbert Irving Comprehensive Cancer Center in New York City. She said it would make sense that research dollars could influence drug choice.

"If you've used a medication in a clinical trial and you have three different agents you can choose from, you have a tendency to go to the agent you're more comfortable with," Hershman said.

By the same token, these smaller gifts -- and the drug company interaction that accompanies them -- might help a doctor feel more knowledgeable and comfortable with that company's products than the other options at their disposal, Mitchell said.

Dr. Erin Aakhus, a cancer specialist with the University of Pennsylvania Perelman School of Medicine, said the new study results warrant further exploration to determine the extent of this influence.

"Financial conflicts of interests may contribute to oncologists' drug selection," Aakhus said. "The influence of the manufacturer on decision-making needs to be considered."

Mitchell said doctors are likely to minimize the influence that small gifts would have on them.

"Physicians feel like everyone else would be influenced by this, but I wouldn't be, personally," he said.

Medical societies such as ASCO try to limit such influence by creating carefully vetted guidelines to help doctors impartially choose the right medication for each patient, Schilsky said.

Hershman said patients also can help by educating themselves on their different treatment options and being engaged in decision making.

"The biggest issue for patients is to be aware," Hershman said. "When they are getting medication, ask their provider if there are other options. Ask the reason they're prescribing that medication as opposed to others."

The study findings were presented at the American Society of Clinical Oncology's annual meeting, in Chicago. Findings presented at meetings are generally viewed as preliminary until they've been published in a peer-reviewed journal.

More information

To check out the Open Payments database, visit Centers for Medicare & Medicaid Services.

SOURCES: Aaron Mitchell, M.D., fellow, University of North Carolina School of Medicine, Chapel Hill; Richard Schilsky, M.D., chief medical officer, American Society of Clinical Oncology; Dawn Hershman, M.D., leader, breast cancer program, Columbia University's Herbert Irving Comprehensive Cancer Center, New York City; Erin Aakhus, M.D., oncologist, University of Pennsylvania Perelman School of Medicine, Philadelphia; June 3, 2017, presentation, American Society of Clinical Oncology meeting, Chicago

Copyright © 2017 HealthDay. All rights reserved. URL:http://consumer.healthday.com/Article.asp?AID=723353

Resources from HONselect: HONselect is the HON's medical search engine. It retrieves scientific articles, images, conferences and web sites on the selected subject.
Neoplasms
Specialty Chemicals and Products
Research Personnel
Leukemia
Kidney
Physicians
Kidney Neoplasms
Leukemia, Myeloid
Leukemia, Myeloid, Chronic
Therapeutics
The list of medical terms above are retrieved automatically from the article.

Disclaimer: The text presented on this page is not a substitute for professional medical advice. It is for your information only and may not represent your true individual medical situation. Do not hesitate to consult your healthcare provider if you have any questions or concerns. Do not use this information to diagnose or treat a health problem or disease without consulting a qualified healthcare professional.
Be advised that HealthDay articles are derived from various sources and may not reflect your own country regulations. The Health On the Net Foundation does not endorse opinions, products, or services that may appear in HealthDay articles.


Home img About us img MediaCorner img HON newsletter img Site map img Ethical policies img Contact